HemOnc Today

CURRENTLY VIEWING:

The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Cover Story

Efforts to reduce racial disparities in cancer care aim to ‘make the invisible visible’

Navigators support, empower minority patients with cancer

Editorial

Big data, big errors of interpretation

Derek Raghavan, MD, PhD

Commentary

Understanding breast implant-associated anaplastic large cell lymphoma

Sameer A. Patel, MD, FACS

Advanced Practice

APP-driven oncology urgent care can improve patient satisfaction, quality of life

Vanna M. Dest, MSN, APRN-BC, AOCN

Imaging Analysis

Periventricular germinoma with leptomeningeal dissemination: A case report

Ana M. Franceschi, MD; Benjamin T. Cooper, MD; David Zagzag, MD; Jonathan Howard, MD; Juhi M. Purswani; Munir Ghesani, MD; Nikhil A. Sahasrabudhe, MD

Feature

‘We have to cure’ cancer, says CAR T pioneer Carl H. June, MD

ASCO president-elect wants ‘new and different viewpoints at the table’

Meeting News

Corticosteroid use for immune-mediated adverse events often does not match guidelines

Fungal infections uncommon among ibrutinib-treated patients despite low rate of prophylaxis

Rapidly expanding treatment options improving survival in acute myeloid leukemia

Cost of cancer care under scrutiny, projected to keep rising

Surgery prolongs survival in HER2-positive advanced breast cancer

Immunotherapy combination of nivolumab, ipilimumab confers benefit in rare neuroendocrine carcinoma

Immunotherapy, chemotherapy combination shows promising antitumor activity in metastatic pancreatic cancer

Gilteritinib represents ‘major change’ for treatment of relapsed, refractory acute myeloid leukemia

Next-generation TRK inhibitor demonstrates efficacy in tumors with emergent resistance mutations

Adults at high risk for HIV show ‘alarmingly’ low HPV vaccination rate

Tools to better assess tumor heterogeneity will ‘shed new light’ on cancer research, treatment

HER2-targeted CAR T cells safely induce responses in advanced HER2-positive sarcoma

CAR T-cell therapy shows promise for mesothelin-expressing solid tumors

Pembrolizumab shows durable benefit as third-line treatment of advanced small cell lung cancer

Experts debate partial breast irradiation vs. omission of radiation therapy for low-risk breast cancer

Work ‘not yet done’ in management of HER2-positive breast cancer

Darolutamide reduces risk for metastases in prostate cancer

Pembrolizumab plus olaparib safe, active in docetaxel-pretreated men with prostate cancer

First-line avelumab, axitinib benefit persists across advanced kidney cancer patient subgroups

Retroperitoneal lymph node dissection demonstrates ‘excellent’ survival rates for testicular seminoma

In the Journals

Lentiviral gene therapy with busulfan conditioning safe, effective in infants with SCID-X1

Opioid-related hospitalizations uncommon, but slowly rising, among patients with cancer

Complementary medicine use common, often undisclosed by patients with, survivors of cancer

FDA News

Recent FDA approvals in oncology

FDA places partial clinical hold on venetoclax trials for multiple myeloma

FDA clears liquid biopsy test to monitor response to chronic myeloid leukemia treatment

FDA weighs breast implant risks, benefits amid links to cancer, other illnesses